The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients with Metastatic Colorectal Cancer
Overview
Authors
Affiliations
Purpose: UGT1A1*28 polymorphism has been associated with decreased glucuronidation of SN38, the active metabolite of irinotecan. This could increase toxicity with this agent.
Patients And Methods: In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment. UGT1A1*28 polymorphism was investigated with respect to the distribution of hematologic and nonhematologic toxicity, objective response rate, and survival. Pharmacokinetics was investigated in a subgroup of patients (71 of 250) who had been analyzed with respect to toxicity and efficacy.
Results: UGT1A1*28 polymorphism was associated with a higher risk of grade 3 to 4 hematologic toxicity (odds ratio [OR], 8.63; 95% CI, 1.31 to 56.55), which was only relevant for the first cycle, and was not seen throughout the whole treatment period for patients with both variant alleles TA7/TA7 compared with wild-type TA6/TA6. The response rate was also higher in TA7/TA7 patients (OR, 0.32; 95% CI, 0.12 to 0.86) compared with TA6/TA6. A nonsignificant survival advantage was observed for TA7/TA7 when compared with TA6/TA6 patients (hazard ratio, 0.81; 95% CI, 0.45 to 1.44). Higher response rates were explained by a different pharmacokinetics with higher biliary index [irinotecan area under the curve (AUC)x(SN38 AUC/SN38G AUC)] and lower glucuronidation ratio (SN38G AUC/SN38 AUC) associated with the TA7/TA7 genotype and a higher response rate, indicating that the polymorphism is functionally relevant.
Conclusion: The results indicate that UGT1A1*28 polymorphism is of some relevance to toxicity; however, it is less important than discussed in previous smaller trials. In particular, the possibility of a dose reduction for irinotecan in patients with a UGT1A1*28 polymorphism is not supported by the result of this analysis.
Ohta H, Yasu T Curr Oncol. 2025; 32(2).
PMID: 39996900 PMC: 11854802. DOI: 10.3390/curroncol32020100.
Roncato R, Bignucolo A, Peruzzi E, Montico M, De Mattia E, Foltran L JAMA Netw Open. 2024; 7(12):e2449441.
PMID: 39641926 PMC: 11624585. DOI: 10.1001/jamanetworkopen.2024.49441.
Sultana R, Chen S, Lim E, Dent R, Chowbay B BJC Rep. 2024; 2(1):85.
PMID: 39528547 PMC: 11554802. DOI: 10.1038/s44276-024-00106-1.
Meta-analysis revisiting the influence of and on irinotecan safety in colorectal cancer patients.
Nguyen C, Nguyen T, Phung T Pharmacogenomics. 2024; 25(10-11):469-477.
PMID: 39171626 PMC: 11492647. DOI: 10.1080/14622416.2024.2385289.
Sanoff H, Deal A, Patel J, Sorah J, Gaddy J, ONeil B Oncologist. 2024; 29(9):786-793.
PMID: 38837045 PMC: 11379652. DOI: 10.1093/oncolo/oyae122.